Laia Garrigos - Publications

A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 19, 2025

Minimally expanded breast cancer tumor-infiltrating-lymphocytes provide guidance for therapeutic selection.

Journal: Frontiers in immunology

Published: September 04, 2025

HLA-DRB1 Allelic Combinations Differentially Shape Dendritic Cell Antigen Presentation Enhanced by Tumour Cell Line Lysate-Pulsing.

Journal: HLA

Published: June 27, 2025

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.

Journal: Breast cancer research : BCR

Published: December 17, 2024

In silico decrypting of the bystander effect in antibody-drug conjugates for breast cancer therapy.

Journal: Scientific reports

Published: November 06, 2024

Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 08, 2024

Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).

Journal: Gynecologic oncology

Published: September 18, 2024

Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer.

Journal: Expert review of anticancer therapy

Published: August 30, 2024

The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis.

Journal: Med (New York, N.Y.)

Published: March 08, 2024

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.

Journal: ESMO open

Published: March 04, 2024

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer.

Journal: International journal of molecular sciences

Published: February 22, 2024

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 21, 2023